Important Safety Information (ISI) is the block of risk information that US prescription drug promotion carries alongside its benefit claims. It is condensed from the approved labeling and typically covers the boxed warning if there is one, contraindications, the most important warnings and precautions, and the most common adverse reactions. The name is an industry convention, not a term FDA's advertising regulation defines, but the requirements it exists to meet are very real.
This article covers the rules the ISI is built to satisfy, how it is presented on web, email, video and character-limited formats, where FDA says risk presentation most often fails, and why, in a modular content system, the ISI is the one component no one assembling an asset should be able to leave out. It is written for the people who make and review promotional content. It is not legal advice, and your own regulatory and legal teams own the interpretation for your products.
Is Important Safety Information an FDA requirement?
Not by that name. The phrase does not appear in 21 CFR 202.1, the regulation that governs prescription drug advertising. What the regulation requires is a true statement of information in brief summary relating to side effects, contraindications and effectiveness, and a fair balance between risk and benefit. The ISI is the format the industry settled on to deliver those requirements in a consistent block that MLR can approve once and reuse.
Because it is a convention, there is no FDA template for its length, order or wording. Each company drafts its own from the prescribing information, and its review committee approves it. FDA does not ask whether a piece has an ISI. It asks whether the piece as a whole conveys the risks accurately and with prominence comparable to the benefits.
A typical ISI opens with the boxed warning, then covers contraindications, the key warnings and precautions, the most common adverse reactions and, where relevant, drug interactions and use in specific populations. In HCP pieces the ISI sits alongside the full prescribing information, not in place of it.
Which FDA rules does the ISI help satisfy?
Fair balance comes first. Under 21 CFR 202.1(e)(5)(ii), an advertisement fails the true statement requirement if it does not present a fair balance between information about side effects and contraindications and information about effectiveness. FDA's 2009 draft guidance on presenting risk information applies the same thinking to promotional labeling, for consumer and HCP audiences alike.
The brief summary is the second. 21 CFR 202.1(e)(1) requires every prescription drug advertisement, apart from the exceptions in (e)(2), to carry a true statement of information in brief summary about side effects, contraindications and effectiveness. In print this is the dense page that follows the ad. FDA's revised draft guidance from 2015 encourages a consumer brief summary in plain language instead of a reprint of the prescribing information.
Broadcast is the third. Under 202.1(e)(1)(i), a TV or radio ad must present the major side effects and contraindications, the major statement, and must also include a brief summary unless adequate provision is made for viewers to get the approved labeling elsewhere. FDA's final rule of 21 November 2023 added a clear, conspicuous and neutral standard for the major statement in DTC TV and radio ads: consumer-friendly language, audio at least as understandable as the rest of the ad, audio and on-screen text together in TV, readable text, and no competing sounds or images while it runs. The compliance date was 20 November 2024.
Adequate provision itself may not last. FDA's regulatory agenda lists a proposed rule, Transparency in Direct-to-Consumer Advertising, that would remove the option, with the proposal targeted for December 2026. As of November 2026 no proposed rule has been published in the Federal Register. We cover what removing adequate provision would mean for broadcast separately. For the ISI, the practical point is that the broadcast version may need to grow.
How should a boxed warning appear in the ISI?
First, and set apart. The ISI mirrors the labeling, where the boxed warning leads. The 2014 draft guidance adds that where a platform allows formatting, a firm should use it to signal the seriousness of a boxed warning, giving bolded text as its example.
A boxed warning also removes options. Reminder ads, which name the product without saying what it is for, skip the brief summary, but the regulation does not permit them for a drug with a boxed warning relating to a serious hazard. In character-limited formats every risk concept in the box has to appear in each message that makes a benefit claim. For some products that makes those formats unusable for branded benefit claims. Decide that at media planning, not in review.
Take Brevanta, a fictional product used here only as an illustration, with a boxed warning for serious infections. A static 300x250 banner cannot hold a benefit headline and a readable boxed warning together. The team can run a scrolling ISI that opens on the boxed warning, move the claim to a format with room for balance, or use unbranded disease awareness. Shrinking the warning to fit is not an option.
Where does ISI go wrong in FDA enforcement letters?
FDA's 2009 draft guidance states that omission or minimization of risk information is the most frequent violation cited in its advertising and promotion enforcement letters. The failures fall into three patterns, and all three can happen in an asset that technically includes an ISI.
Omitted: a risk from the label is missing. It usually happens when copy is shortened for a new channel and a contraindication or adverse reaction drops out. Leaving out a limitation of use belongs here too, because it changes how the benefit reads.
Minimized: the risk is present but framed to sound smaller. Reassuring qualifiers, technical language for a consumer audience while the benefits are in plain English, or a strong benefit headline with no matching heading for the risks. The 2009 guidance discusses these signals directly: a headline that signals benefit information should be matched by one that signals risk.
Less prominent: the risk is complete but harder to see. Smaller type, lower contrast, placement far below the claims, a link instead of text, a crawl too fast to read, or a voiceover running under an upbeat montage.
Why can a modular content system never make the ISI optional?
Modular content builds assets from approved components: a claim, a statistic, an image, a line of copy. Most are choices: use the statistic or not, swap the image, pick a shorter headline. The ISI is not. Any asset that makes a benefit claim, which is everything except a true reminder, needs it. So treat it as a locked component: the assembler can place it, cannot edit it, and cannot publish without it.
Version it against the label. Each ISI component should record the prescribing information version it was approved against, and should come in approved variants for each format: the full ISI, the most-serious-risks version for character-limited messages, and the broadcast major statement with its on-screen supers. Every variant points to the same label version. The template rule follows: a module carrying a benefit claim cannot go out without the ISI variant for its channel.
This is where label changes get easier. A claim change touches the assets that use that claim. An ISI change touches every promotional asset for the brand. With the ISI as one versioned component, a new warning means updating one component, re-approving its variants, and pulling a list of every live asset still on the old version.
Locking the ISI is necessary, not sufficient. Balance is judged across the whole piece, so an asset assembled entirely from approved modules can still overweight benefit through layout, pacing or visuals. Our fair balance guide covers how reviewers judge that.
Where SwishX fits
Magic Studio builds every asset from the Brand Dossier, the single source of truth that holds a brand's claims, evidence, ISI and fair balance language alongside its audience and channel requirements. Fair balance and safety information are placed in the asset as it is made, across Video, Visual Aids, Ads, Approved Email and Web, and every claim is cited to its source and checked against the label for its market.
Because every asset traces back to one dossier, the safety information in a video script, a detail aid and an email comes from the same place rather than three retyped copies. Finished work goes into your MLR queue and on into Veeva PromoMats with every claim and its reference attached. See how it works in Magic Studio.
Frequently asked questions
What does ISI stand for in pharma?
ISI stands for Important Safety Information, the block of risk information drawn from the approved labeling that accompanies prescription drug promotion. It usually covers the boxed warning, contraindications, key warnings and precautions, and the most common adverse reactions.
Is ISI required by the FDA?
Not by name. FDA's advertising regulation, 21 CFR 202.1, requires fair balance between risk and benefit and a brief summary of side effects, contraindications and effectiveness. The ISI is the industry's standard way of meeting those requirements in each asset.
What is the difference between ISI and the brief summary?
The ISI is a condensed safety section placed in the asset itself, near the claims it balances. The brief summary is the fuller risk disclosure required for prescription drug advertisements, which in print usually appears as a separate page after the ad.
What is a scrolling ISI?
A scrolling ISI is safety information that stays on screen in a fixed panel, or scrolls inside a banner frame, so the risks remain visible while the user reads the claims. It is an industry convention for web and display formats, not a format FDA prescribes.
Does a social media post need ISI?
Under FDA's 2014 draft guidance, a character-limited post that makes a benefit claim should include at least the most serious risks, such as the boxed warning concepts, fatal or life-threatening risks and contraindications, plus a direct link to fuller risk information. If that does not fit, FDA suggests reconsidering the platform for that message.